wp_suba – RUBYnanomed
28 de September, 2022

Best-in-class canceR dIaGnostic cHip for patient sTratification

Project acronym: BRIGHT Project name: Best-in-class canceR dIaGnostic cHip for patient sTratification. Project co-funded by the: European Innovation Council Project number: 190138134 Project Description:Through advanced microengineering […]
22 de January, 2022

Discriminating Epithelial to Mesenchymal Transition Phenotypes in Circulating Tumor Cells Isolated from Advanced Gastrointestinal Cancer Patients

3 de September, 2021

HER2 Expression in Circulating Tumour Cells Isolated from Metastatic Breast Cancer Patients Using a Size-Based Microfluidic Device

24 de May, 2021

RUBYnanomed is part of the 2021 IGNITE Cohort

MassMEDIC, the Massachusetts Medical Device Industry Council, announced today the 2021 IGNITE Cohort, and RUBYnanomed was one of the awarded medtech startups. Press release: follow the link
18 de August, 2020

RUBYnanomed highlighted as a startup to watch by cLAB Ventures

cLAB Ventures launched a mentorship programme to accelerate the business development of startups innovating in the field of oncology, and RUBYnanomed was highlighted as a startup […]
24 de July, 2020

RUBYnanomed gets support from La Caixa Foundation

RUBYnanomed was awarded the prestigious Caixa Impulse Consolidate funds to help the fight against cancer. The project intends to build an automated system for non-invasive diagnosis […]
5 de November, 2019

RUBYnanomed awarded as an emerging technology in health by the Royal Society of Chemistry

The Emerging Technologies Competition is the Royal Society of Chemistry’s annual initiative for early stage companies and academic entrepreneurs who want to commercialise their technologies to […]
29 de May, 2019

The Significance of Circulating Tumour Cells in the Clinic

21 de October, 2018

Next Big Idea (SIC Notícias)

Sara Abalde mostra-nos um dispositivo transparente que tem lá dentro um circuito que quase parece uma pauta de música. É um objeto pequenino, talvez com menos […]